Researchers from the RHAPSODY study, which is examining the efficacy of adalimumab (Humira) on ankylosing spondylitis, report that the incidence of uveitis is markedly reduced among patients receiving the anti-TNF treatment.
Labels: humira, research, tnf, uveitis
Comments on this post
Post a Comment
Links to this post
Create a Link